Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics is a publicly traded biotechnology firm focused on oncolytic virus therapy — a modality that uses replicating viruses to infect and lyse cancer cells while stimulating an antitumor immune response. The company was formed around technology developed by co-founder Dr. John Yu, a surgical oncologist and researcher at Cedars-Sinai Medical Center. It went public in October 2022 through a merger with a SPAC, listing on NYSE American. The firm's platform uses stem cells as delivery vehicles for oncolytic viruses, including its lead candidate CLD-101 for recurrent glioblastoma. Calidi also has a preclinical program CLD-201 for solid tumor indications. The approach faces competition from global oncology players and other biotechs like Replimune (RP1) and CG Oncology. As a public company, Calidi reports financials quarterly, with research and development expenses dominating cash burn. Calidi employs under 30 staff per SEC filings, with headquarters in the United States. The company has not disclosed a family-office affiliation or wealth origin for its backers. Its largest institutional shareholder as of 2024 filings included entities tied to Dr. Yu and other early investors. No recent operational event was identified in public filings or SEC records beyond routine quarterly updates. As a publicly traded entity, Calidi differs from traditional family offices in that it must disclose material events via SEC filings and maintain board governance. However, the tighter ownership structure — concentrated among founding insiders — can resemble a family-office posture, with strategic decisions made at the board level rather than through dispersed public shareholders.